NCT06401278

Brief Summary

To compare between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension BACKGROUND: The current American College of Cardiology and the American Heart Association (ACC/AHA) 2017 guidelines define hypertension as systolic BP (SBP) of ≥130 mmHg or diastolic BP (DBP) of ≥80 mmHg. In adults, an increase of 20 mmHg in SBP or 10 mmHg in DBP is associated with more than a two-fold increase in mortality owing to stroke and other cardiovascular diseases. Hypertension accounts for 13% of premature deaths worldwide and is the third leading cause of disability-adjusted life years (Shah et al., 2022). Transcutaneous electrical nerve stimulation of the Neiguan (P6) point with acupressure is possibly affecting the blood pressure by protecting the myocardial tissues and influencing the nervous system through regulating the autonomic nervous system function and reduction in sympathetic activity. (Hassanein et al., 2021). HYPOTHESES There will be no a significant difference between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension RESEARCH QUESTION: Is there a significant difference between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension? Evaluating equipment, pre-post intervension outcomes:

  1. 1.BP by Digital Sphygmomanometer
  2. 2.quality of life by The SF-12 health status questionnaire
  3. 3.nitric oxide level in blood by nitric Oxide analysis.
  4. 4.sleep quality. by Pittsburgh Sleep Quality Index (PSQI)
  5. 5.exercise capacity and endurance by Thirty-Second Sit-To-Stand Test (30 STST)

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable hypertension

Timeline
Completed

Started May 2024

Shorter than P25 for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 2, 2024

Completed
3 days until next milestone

Study Start

First participant enrolled

May 5, 2024

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 6, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 5, 2024

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 10, 2024

Completed
Last Updated

May 7, 2024

Status Verified

May 1, 2024

Enrollment Period

3 months

First QC Date

May 2, 2024

Last Update Submit

May 5, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Blood Pressure by using a digital sphygmomanometer

    Blood pressure was recorded by using a digital sphygmomanometer

    six weeks

  • quality of life by Short Form twelve health status questionnaire

    by Short Form twelve health status questionnaire Health-Related Quality of Life survey consisting of twelve questions that measure eight health domains to assess physical and mental health.The score ranges from 0 to 100, with a higher score indicating better physical and mental health functioning.

    six weeks

  • Nitric oxide by nitric oxide sample analysis

    by nitric oxide sample analysis

    six weeks

Secondary Outcomes (2)

  • exercise capacity and endurance measured by Thirty-Second Sit-To-Stand Test (30 STST)

    six weeks

  • sleep quality

    six weeks

Study Arms (3)

Transcutaneous electrical acupoint stimulation (Group A):

EXPERIMENTAL

Transcutaneous electrical acupoint stimulation :It will be performed by using the TENS device on acupoint (TEAS) as the following: The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)

Device: Transcutaneous electrical acupoint stimulation

Transcutaneous electrical nerve stimulation(Group b):

EXPERIMENTAL

TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.

Device: Transcutaneous electrical nerve stimulation (group b):

Control

NO INTERVENTION

Routine medical treatment: (Group c): receive only routine medical treatment (antihypertensive medication, instructions and education to control blood pressure) * Nutrition Eat a diet that is high in fiber and potassium, and low in salt (sodium), added sugar, and fat. * Lifestyle Do not use any products that contain nicotine or tobacco, such as cigarettes, and chewing tobacco. * Identify your sources of stress and find ways to manage stress. This may include deep breathing or making time for fun activities. * Do not drink alcohol

Interventions

It will be performed by using the TENS device on acupoint (TEAS) as the following: The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)

Transcutaneous electrical acupoint stimulation (Group A):

TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.

Transcutaneous electrical nerve stimulation(Group b):

Eligibility Criteria

Age50 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • \) Sixty patients from both sexes diagnosed with essential HT at least 6 months ago.
  • \) Their age will be ranged from 50 to 60 years old. 3) Their blood pressure will be ranged from (SBP is 140 -159 mmHg and/or DBP is 90-99 mmHg).
  • \) Their body mass index (BMI) ranged from will be ranged from 24.9 to 29.9 kg/m2.
  • \) All patients are medically stable and receive the same medical treatment 6) All patient nonsmoker or quitted smoking for at least 4-5 years 7) All patients will be similar in terms of status of functional activity, status of eating a salt-free diet and the presence of any chronic disease except HT

You may not qualify if:

  • \) Secondary hypertension 2) Patients with cardiac problems e.g. atrial fibrillation, left bundle-branch block, heart failure, recent myocardial infarction, coronary artery disease, or participation in cardiac rehabilitation following bypass surgery.
  • \) Patients with history, symptoms of, and/or laboratory reports suggestive of renal, neurologic, or hepatic complications.
  • \) Use of a cardiac pacemaker 5) Any metal implants at site of application of TENS 6) Dermatological abnormalities at the site of the application of TENS 7) Obesity with body mass index (BMI) \> 30 kg/m2 8) Smoker, diabetes. 9) Soft tissue, nerve, and vascular diseases of upper or lower extremities which hinder the application of TEAS.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of physical therapy- Cairo Uni.

Giza, 12611, Egypt

RECRUITING

MeSH Terms

Conditions

Hypertension

Interventions

Transcutaneous Electric Nerve Stimulation

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsPhysical Therapy ModalitiesRehabilitationAnalgesiaAnesthesia and Analgesia

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Lecturer

Study Record Dates

First Submitted

May 2, 2024

First Posted

May 6, 2024

Study Start

May 5, 2024

Primary Completion

August 5, 2024

Study Completion

August 10, 2024

Last Updated

May 7, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations